阿托伐他汀钙片治疗脑卒中并脑微出血的临床研究(1)
摘要：目的 探讨阿托伐他汀钙片治疗脑卒中并脑微出血的疗效及安全性。方法 选取我院2016年1月～2018年1月收治的112例脑卒中并脑微出血患者为观察对象，按照随机数表法分为对照组和研究组，每组56例。两组均给予常规治疗，研究组加用阿托伐他汀钙片治疗，比较两组疗效、不良反应、出血病灶数量。结果 研究组总有效率高于对照组(92.86% vs 75.00%)，差异有统计学意义(P<0.05);治疗后两组出血病灶数量均减少，其中研究组治疗后出血病灶为(2.16±1.74)个，少于对照组的(4.23±1.98)个，差异有统计学意义(P<0.05);研究组不良反应率高于对照组(14.29% vs 10.71%)，但差异无统计学意义(P>0.05)。结论 阿托伐他汀钙片可减少脑卒中并脑微出血患者的出血病灶，提高临床疗效，且不会增加不良反应。
关键词：脑卒中;脑微出血;阿托伐他汀钙片;出血病灶
中图分类号：R743.3 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.15.048
文章编号：1006-1959(2019)15-0147-02
Abstract：Objective To investigate the efficacy and safety of atorvastatin calcium tablets in stroke and cerebral microhemorrhage. Methods A total of 112 patients with stroke and cerebral microhemorrhage admitted to our hospital from January 2016 to January 2018 were enrolled in the study. They were divided into control group and study group according to the random number table method， with 56 cases in each group. Routine treatment was given to both groups， and the study group was treated with atorvastatin calcium tablets. The efficacy， adverse reactions， and number of bleeding lesions were compared between the two groups.Results The total effective rate of the study group was higher than that of the control group (92.86% vs 75.00%)， the difference was statistically significant (P<0.05). The number of hemorrhagic lesions decreased after treatment， and the hemorrhagic lesions in the study group were (2.16±1.74)， less than the control group (4.23±1.98)， the difference was statistically significant (P<0.05); the adverse reaction rate of the study group was compared with the control group (14.29% vs 10.71%)， the difference was not statistically significant (P>0.05).Conclusion Atorvastatin calcium tablets can significantly reduce the bleeding of patients with stroke and cerebral microhemorrhage， improve clinical efficacy， and will not increase adverse reactions.
Key words：Stroke;Cerebral microhemorrhage;Atorvastatin calcium tablets;Hemorrhagic lesions
脑微出血(cerebral microhemorrhage)是指出血病灶直径10 mm以下的出血，由脑内微小血管发生病变引起。脑卒中患者是其的高发人群，脑微出血在缺血性脑卒中患者中发生率为21%～26%，在出血性脑卒中患者中发生率约68%，致病因素包括血管炎、脑淀粉样病变等[1]。目前，尚缺乏公认的介绍脑卒中并脑微出血的治疗指南。因此，探尋治疗脑卒中并脑微出血的有效、安全方案是研究重点。阿托伐他汀钙片属于胆固醇合成限速酶(HMG-CoA)还原酶抑制剂，具有降脂、抑制血小板聚集、保护血管内皮、改善氧化应激反应等作用。本研究将阿托伐他汀钙片用于治疗脑卒中并脑微出血患者，观察其疗效及安全性，现报道如下。, 百拇医药(陈曦 寇天)
关键词：脑卒中;脑微出血;阿托伐他汀钙片;出血病灶
中图分类号：R743.3 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.15.048
文章编号：1006-1959(2019)15-0147-02
Abstract：Objective To investigate the efficacy and safety of atorvastatin calcium tablets in stroke and cerebral microhemorrhage. Methods A total of 112 patients with stroke and cerebral microhemorrhage admitted to our hospital from January 2016 to January 2018 were enrolled in the study. They were divided into control group and study group according to the random number table method， with 56 cases in each group. Routine treatment was given to both groups， and the study group was treated with atorvastatin calcium tablets. The efficacy， adverse reactions， and number of bleeding lesions were compared between the two groups.Results The total effective rate of the study group was higher than that of the control group (92.86% vs 75.00%)， the difference was statistically significant (P<0.05). The number of hemorrhagic lesions decreased after treatment， and the hemorrhagic lesions in the study group were (2.16±1.74)， less than the control group (4.23±1.98)， the difference was statistically significant (P<0.05); the adverse reaction rate of the study group was compared with the control group (14.29% vs 10.71%)， the difference was not statistically significant (P>0.05).Conclusion Atorvastatin calcium tablets can significantly reduce the bleeding of patients with stroke and cerebral microhemorrhage， improve clinical efficacy， and will not increase adverse reactions.
Key words：Stroke;Cerebral microhemorrhage;Atorvastatin calcium tablets;Hemorrhagic lesions
脑微出血(cerebral microhemorrhage)是指出血病灶直径10 mm以下的出血，由脑内微小血管发生病变引起。脑卒中患者是其的高发人群，脑微出血在缺血性脑卒中患者中发生率为21%～26%，在出血性脑卒中患者中发生率约68%，致病因素包括血管炎、脑淀粉样病变等[1]。目前，尚缺乏公认的介绍脑卒中并脑微出血的治疗指南。因此，探尋治疗脑卒中并脑微出血的有效、安全方案是研究重点。阿托伐他汀钙片属于胆固醇合成限速酶(HMG-CoA)还原酶抑制剂，具有降脂、抑制血小板聚集、保护血管内皮、改善氧化应激反应等作用。本研究将阿托伐他汀钙片用于治疗脑卒中并脑微出血患者，观察其疗效及安全性，现报道如下。, 百拇医药(陈曦 寇天)